• About us
  • Core Technology
  • Bio-Service
  • Investors
  • Careers
中文 English
  • About us
    • Introduction
    • Information
      • Announcement
      • Events
      • Corporate image
    • Management Team
      • Members
      • Consultants
    • Contact us
  • Core Technology
    • New medicine development platform
      • Skin diseases
        • ENERGI-F703 ENERGI-F701 ENERGI-F711
      • metabolic diseases
        • ENERGI-F702
      • Anti-inflammation
        • ENERGI-F704 ENERGI-F708
      • Diseases related to deficient mitochondrion
        • ENERGI-F705 ENERGI-F707
      • Others
        • ENERGI-F706 ENERGI-F709 ENERGI-F710
  • Bio-Service
    • Scientific products
      • Western Blot
      • Cell Culture Supplement
      • Protein Isolation
      • Protein Quantification
      • Dyes and Buffer
    • Supplier
      • Lumiprobe
      • Rigaku Reagents
    • Service
      • Quantitative MS and systematic biological analysis experiment service
      • Protein identity certification experiment service
      • Microarray and biological information analysis experiment service
  • Investors
    • Company
    • Financial information
      • Monthly revenue information
      • Financial report
    • Shareholders
      • Shareholders' Meeting
      • Dividend policy and dividend distribution
      • Public specification
      • Stock price information
      • Corporate briefing
      • Important information
      • Investment service window
      • Links
    • Corporate Governance
      • Member of the board
      • Functional committee
      • Various management measures
      • Internal audit
      • Head of Corporate Governance
    • Corporate social responsibility
      • Performance of corporate responsibility
      • Corporate Integrity Zone
      • Stakeholder
  • Careers

About us

  • >
  • About us
  • >
  • Information
  • >
  • Announcement
  • Introduction
  • Information
    • Announcement
    • Events
    • Corporate image
  • Management Team
    • Members
    • Consultants
  • Contact us
2017-07-24
The A+ business innovation funding project, sponsored by the Ministry of Economic Affairs ROC, passed

The project of phase II clinical trial ENERGI-F703, gel for treating diabetic foot ulcer, has passed the audit of the A+ business innovation funding project sponsored by the Ministry of Economic Affairs ROC.

Back
  • +886-2-26270835
  • +886-2-26270836
  • 6F.-3, No.21, Ln.583, Ruiguang Rd., Neihu Dist., Taipei 11492, Taiwan (R.O.C.)
Copyright © 20204 ENERGENESIS BIOMEDICAL CO., LTD. All Rights Reserved. Design by choice